Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §4

Cognitive performance and neuroprotection — compounds assessed

The 7 compounds the Institute assesses in cognitive performance and neuroprotection.

Document identifier
CEI-IN-27/4
Series
Indication assessment
Version
2.3
Published
15 Feb 2025
Last reviewed
15 Feb 2025
Next review
15 Feb 2027
Identifier
10.71829/cei.ind.27
Certainty
Not rated
Cycle
2025 Q1
ICD-11
MB21
Category
Neuropsychiatric

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

  • Endogenous tripeptide thiol antioxidant1 contributing trialfull monograph

    Small randomised trials of intravenous and intranasal glutathione in Parkinson disease reported no significant benefit over placebo on motor endpoints — The available randomised evidence is negative rather than absent, which the Institute distinguishes.

    Low
  • Endogenous nonapeptide0 contributing trialsfull monograph

    No assessable evidence identified — —

    Very low
  • Synthetic tetrapeptide0 contributing trialsfull monograph

    No assessable evidence identified — —

    Very low
  • Endogenous pyridine dinucleotide coenzyme0 contributing trialsfull monograph

    No assessable randomised evidence identified — —

    Very low
  • Synthetic tuftsin analogue heptapeptide1 contributing trialfull monograph

    Russian clinical studies report anxiolytic effect comparable to benzodiazepines without sedation or withdrawal — Downgraded for risk of bias and reporting limitations. A claim of benzodiazepine-equivalent anxiolysis without dependence would be a substantial…

    Very low
  • Synthetic ACTH(4-10) analogue heptapeptide2 contributing trialsfull monograph

    Russian clinical studies report functional improvement after ischaemic stroke and in cognitive disorders — Downgraded to very low for risk of bias and reporting limitations rather than for absence of studies. The Institute distinguishes these two reasons for…

    Very low
  • 28-residue N-acetylated thymic polypeptide0 contributing trialsfull monograph

    No evidence identified — —

    Not rated

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.